Recommended Protocol for the Study of the Ex Vivo Biological Effects of Virus-Inactivated Plasma Concentrates in Patients with von Willebrand Disease

• References

• 1 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemostas Thromb 1986; 8: 19-45
• 2 Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991; 5: 155-161
• 3 Bennet EA, Dormandy K. Pool’s cryoprecipitate and exhausted plasma in the treatment of von Willebrand’s disease and factor XI deficiency. Lancet 1966; 91: 731-732
• 4 Perkins HA. Correction of the hemostatic defects in von Willebrand’s disease. Blood 1967; 30: 375-380
• 5 Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988; 2: 782-785
• 6 Kohler M, Hellstern P, Wenzel E. The use of heat-treated factor-VIII concentrates in von Willebrand’s disease. Blut 1985; 50: 25-27
• 7 Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988; 40: 205-214
• 8 Fukui H, Nishino M, Terada S, Nishikubo T, Yoshioka A, Kinoshita S, Niinomi K, Yoshioka K. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand’s disease. Blut 1988; 56: 171-178
• 9 Czapek EE, Gadarowksi Jr JJ, Ontiveros JD, Pedraza JL. Humate P for treatment of von Willebrand disease. Blood 1989; 73: 1100 (letter)
• 10 Mazurier C, De Romeuf C, Parquet-Gernez A, Goudemand M. In vitro and in vivo characterization of a high purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand’s disease. Eur J Haematol 1989; 43: 7-14
• 11 Pasi KJ, Williams MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand’s disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 1990; 75: 228-233
• 12 Cumming AM, Fildes S, Cumming IR, Wensley RT, Redding OM, Burn AM. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand’s disease. Br J Haematol 1990; 75: 234-239
• 13 Ruggeri ZM, Mannucci PM, Jeffcoate SL, Ingram GIC. Immunoradiometric assay of factor VIII related antigen with observations in 32 patients with von Willebrand’s disease. Br J Haematol 1976; 33: 221-232
• 14 Mannucci PM, Lattuada A, Castaman G, Lombardi R, Colibretti ML, Ciavarella N, Rodeghiero F. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. Blood 1989; 74: 2433-2436
• 15 Mannucci PM, Lombardi R, Bader R, Vianello L, Federici AB, Solinas S, Mazzucconi MG, Mariani G. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66: 796-802
• 16 Gralnick HR, Rick ME, McKeown LP, Williams SB, Parker RI, Maisonneuve P, Janneau C, Sultan Y. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand’s disease. Blood 1980; 68: 58-61
• 17 Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood 1982; 59: 1272-1278
• 18 Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by l-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease. N Engl J Med 1983; 309: 816-821
• 19 McLeod BC, McKenna R, Sassetti RJ. Treatment of von Willebrand’s disease and hypofibrinogenemia with single donor cryoprecipitate from plasma exchange donation. Am J Hematology 1989; 32: 112-116
• 20 Weiss JH. Relation of von Willebrand factor to bleeding time. N Engl J Med 1970; 291: 420 (letter)
• 21 Chediak JR, Telfer MC, Green D. Platelet function and immunologic parameters in von Willebrand’s disease following cryoprecipitate and factor VIII concentrate infusion. Am J Med 1977; 62: 369-376
• 22 Green D, Potter EV. Failure of AHF concentrate to control bleeding in von Willebrands disease. Am J Med 1976; 60: 357-360
• 23 Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 1976; 236: 2770-2772
• 24 Mannucci PM, Moia M, Rebulla P, Altieri D, Monteagudo J, Castillo R. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987; 25: 55-65
• 25 Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. ; Vox Sanguinis: 1992. in press
• 26 Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 1977; 60: 390-404
• 27 Kernoff PBA, Rizza CR, Kaelin AC. Transfusion and gel filtration studies in von Willebrand’s disease. Br J Haematol 1974; 28: 357-370
• 28 Mannucci PR, Abildgaard CF, Gralnick HR, Hill FGH, Hoyer LW, Lombardi I, Nilsson IM, Tuddenham E, Meyer D. Multicenter comparison of von Willebrand factor multimer sizing techniques. Thromb Haemostas 1985; 54: 873-879